HeartWare Gets FDA Panel Date For HVAD Heart Failure Implant
This article was originally published in The Gray Sheet
Executive Summary
Advisory panel review April 25 could pave the way for PMA approval this year as a bridge to heart transplant.
You may also be interested in...
FDA Panel Supports HeartWare VAD, Despite Trial Shortcomings
Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.
Regulatory News In Brief
Industry responds favorably to FDA's early-feasibility-study draft guidance. Circulatory System Devices panel to vote on HeartWare and Cameron Health devices. More regulatory news.
HeartWare Pipeline Update: HVAD On Track For 2012 PMA Approval
Firm notes that it has not yet heard from FDA on whether an advisory committee review will be required for its left ventricular assist device, intended as a bridge to transplant.